• 1
    Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012;18:10291036.
  • 2
    Pearl J. Understanding propensity scores. In: Pearl J, ed. Causality: Models, Reasoning and Inference. 2nd ed. Cambridge, MA: Cambridge University Press; 2009:348351.
  • 3
    McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011;11:23792387.
  • 4
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al.; for H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012;12:30083020.
  • 5
    Saliba F, De Simone P, De Carlis L, Metselaar HJ, Beckebaum S, Jonas S, et al. Everolimus with reduced tacrolimus exposure versus standard tacrolimus in hepatitis C virus positive de novo liver transplant recipients [abstract]. Liver Transpl 2012;18(suppl 1):S98.